| Patent application number | Description | Published |
|---|
| 20090278467 | DIMMABLE ELECTRONIC BALLAST FOR ELECTRODELESS DISCHARGE LAMP AND LUMINAIRE - A dimmable electronic ballast for an electrodeless discharge lamp comprises an inverter circuit, a resonance circuit, an induction coil and a start circuit. The start circuit has a variable time constant. The start circuit sweeps a drive frequency of the inverter circuit through a time constant for start or restart so that the voltage applied across the coil is raised from voltage lower than start voltage and restart voltage for starting and restarting the lamp to voltage higher than the start voltage and the restart voltage. The time constant for start during a start period for starting the lamp is larger than the time constant for restart during a restart period for restarting the lamp. | 11-12-2009 |
| 20100194305 | ELECTRONIC BALLAST FOR DISCHARGE LAMP - An electronic ballast for a discharge lamp includes a predictive circuit and a correction circuit in addition to a power conversion circuit including an inverter circuit and a resonant circuit, a drive circuit and a frequency control circuit. The inverter circuit applies load voltage across a load circuit including the lamp via the resonant circuit. The predictive circuit predicts a resonance frequency of the combination of the resonant circuit and the load circuit after ignition of the lamp. The resonance frequency is predicted based on an input signal representing the load voltage in the period of time from the start of sweep of the inverter circuit's operating frequency through a time point immediately after ignition of the lamp. The correction circuit changes the end frequency of the sweep to the resonance frequency. | 08-05-2010 |
| 20110095691 | Lighting Apparatus And Lighting Fixture - A lighting apparatus includes a lighting circuit unit, a timer unit, a life judgment unit, a timing adjustment unit, and an indication unit. The lighting circuit unit is configured to activate a light source. The timer unit is configured to measure accumulated operation time of the lighting circuit unit. The life judgment unit is configured to store a first judgment time and a second judgment time longer than the first judgment time. The life judgment unit is configured to compare the accumulated operation time with the first judgment time and output a first judgment signal when the accumulated operation time becomes equal to the first judgment time. The life judgment unit is configured to compare the accumulated operation time with the second judgment time and output a second judgment signal when the accumulated operation time becomes equal to the second judgment time. The timing adjustment unit is configured to vary timing at which the life judgment unit outputs the first judgment signal. The timing adjustment unit is configured to vary timing at which the life judgment unit outputs the second judgment signal. The indication unit is configured to indicate, upon receiving the first judgment signal from the life judgment unit, a first level of the end of life with the light source kept turned on. The indication unit is configured to indicate, upon receiving the second judgment signal from the life judgment unit, a second level of the end of life. The second level of the end of life is later than the first level of the end of life. | 04-28-2011 |
| Patent application number | Description | Published |
|---|
| 20090130131 | Antigen-Drug Vehicle Enabling Switch From Selective Production of IgA Antibody to Production of Both of IgA and IgG Antibodies and Transnasal/Mucosal Vaccine Using the Same - In the aim of practical utilization of a safe and effective transnasal/inactivated/mucosal vaccine and establishment of a technology for imparting capacity of producing both of IgA and IgG antibodies to a conventional inactivated vaccine, toxoid; allergen, or the like, a means for prevention and treatment of allergy, and the like, it is intended to provide an antigen-drug vehicle (AD vehicle) enabling transnasal, transmucosal, and transdermal administrations, an inactivated vaccine simultaneously inducing a mucosal immunity and humoral immunity by using the AD vehicle, a production method of the inactivated vaccine, an AD vehicle enabling a switch from induction of selective production of IgA antibody to induction of both of IgA and IgG antibodies, and a transnasal vaccine, a mucosal vaccine, a therapeutic/prophylactic agent for allergy, and the like using the AD vehicle. | 05-21-2009 |
| 20100086939 | DETERMINATION METHOD FOR ALLERGIC DISEASE - It is to provide a method for determining allergic diseases with a high sensitivity and accuracy which enables multilateral and global analysis with a minute amount of sample, even using body fluid other than blood such as saliva, nasal discharge and tears as a sample, particularly by suppressing nonspecific reaction as much as possible. A chemically modified diamond/DLC (Diamond-like Carbon) chip is activated with a reacting reagent, a coupling reaction with a peptide comprising allergen or allergen epitope is conducted, and a sample such as saliva, tears, and nasal discharge which has undergone pressure filtration with a low protein-adsorbing filter, is contacted with an allergen determination chip to which washing and blocking operations have been performed on unreacted active groups, and an allergen recognizing antibody in the sample captured by the allergen determination chip is detected by immunoassay using a labeled secondary antibody, wherein a glycine-containing solution is used for a washing solution and/or blocking solution used in the washing and blocking operations, is used. | 04-08-2010 |
| 20100323904 | Transcription chip - A transcription chip comprising a substrate and, immobilized thereon, at least one polynucleotide including an element sequence to which a transcription factor can be bound. | 12-23-2010 |
| 20110110971 | ANTIGEN-AND-DRUG VEHICLE COMPRISING SYNTHETIC PEPTIDE, AND MUCOSAL VACCINE USING THE SAME - Disclosed are an antigen-and-drug (AD) vehicle and a mucosal vaccine utilizing a novel synthetic peptide. | 05-12-2011 |
